Pathfinder Medical, operating under the brand Stent Tek, is pioneering a novel electronic guidance system designed to enable clinicians to connect blood vessels in a minimally invasive manner. This technology is particularly beneficial for patients requiring vascular access for dialysis and other vascular procedures. The company serves a global market, addressing the needs of approximately 200 million patients, including 22-30 million with the most advanced stage of chronic total occlusion (CTO). Pathfinder Medical's core product is an electronic catheter guidance platform that ensures safe needle crossing and guidewire placement across vessels, significantly improving procedural outcomes and reducing the need for surgical interventions.

The business model of Pathfinder Medical revolves around the development and commercialization of its proprietary endovascular guidance technology. Revenue is generated through the sale of these advanced medical devices to healthcare providers and institutions. The company has successfully secured Series A funding from institutional investors, highlighting the financial community's confidence in its innovative approach and market potential.

Pathfinder Medical's market includes hospitals, clinics, and specialized medical centers that perform vascular procedures. The company's technology is particularly relevant in the context of dialysis, where there is a high demand for reliable and minimally invasive vascular access solutions. By improving the safety and efficacy of these procedures, Pathfinder Medical aims to reduce the incidence of complications and enhance patient quality of life.

Keywords: electronic guidance system, vascular procedures, minimally invasive, dialysis, chronic total occlusion, catheter guidance, needle crossing, guidewire placement, medical devices, healthcare providers.